The fastest-growing and largest of the 20 sized Pharmaceuticals markets in Japan, 2023 to 2033, with active clinical trials.
| # | Market | 2023 | 2033 (projected) | CAGR | Active trials |
|---|---|---|---|---|---|
| 1 | Biosimilars | $2.3 Bn | $22.1 Bn | 25.4% | 14 |
| 2 | Cell Based Immunotherapy | $1 Bn | $8.5 Bn | 23.5% | 773 |
| 3 | Cannabidiol (CBD) | $1.4 Bn | $6.8 Bn | 17.3% | 1 |
| 4 | Cannabis | $2.1 Bn | $7.8 Bn | 14% | 0 |
| 5 | Atopic Dermatitis Drugs | $698 Mn | $2.3 Bn | 12.7% | 28 |
| 6 | Oncology/Cancer Drugs | $11 Bn | $25.8 Bn | 8.9% | 1,084 |
| 7 | Anti-Aging | $5.5 Bn | $12.5 Bn | 8.6% | 20 |
| 8 | Diabetes Management | $4.8 Bn | $10.1 Bn | 7.6% | 53 |
| 9 | Alzheimer Drugs | $311 Mn | $630 Mn | 7.3% | 43 |
| 10 | Contraceptives Drugs | $1.6 Bn | $3.2 Bn | 7.3% | 0 |
| # | Market | 2023 | 2033 (projected) | CAGR | Active trials |
|---|---|---|---|---|---|
| 1 | Oncology/Cancer Drugs | $11 Bn | $25.8 Bn | 8.9% | 1,084 |
| 2 | Anti-Aging | $5.5 Bn | $12.5 Bn | 8.6% | 20 |
| 3 | Diabetes Management | $4.8 Bn | $10.1 Bn | 7.6% | 53 |
| 4 | Gastrointestinal Drugs | $3.4 Bn | $5.5 Bn | 5.1% | 326 |
| 5 | Asthma & COPD Drugs | $3.1 Bn | $4.8 Bn | 4.5% | 55 |
| 6 | Biosimilars | $2.3 Bn | $22.1 Bn | 25.4% | 14 |
| 7 | Cannabis | $2.1 Bn | $7.8 Bn | 14% | 0 |
| 8 | HIV Drugs | $1.9 Bn | $3.4 Bn | 6.3% | 9 |
| 9 | Contraceptives Drugs | $1.6 Bn | $3.2 Bn | 7.3% | 0 |
| 10 | Cancer Supportive Care Drugs | $1.5 Bn | $2.6 Bn | 5.2% | 132 |
2033 values are projected from the 2023 size and the CAGR. Each market name opens its report. Active trials: recruiting, about to start or running.
Biosimilars grows fastest, at 25.4% a year from 2023 to 2033, ahead of Cell Based Immunotherapy (23.5%).
Oncology/Cancer Drugs is the largest, worth about $11 Bn in 2023 and $25.8 Bn by 2033 (projected).
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide.